Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
THE WOODLANDS, Texas, March 05, 2009 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. , a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that Dr. Philip Brown, senior vice president of clinical development at Lexicon, delivered an oral presentation at the annual meeting of the European Neuroendocrine Tumor Society (ENETS). The presentation summarized Phase 1 clinical trial results for LX1032, Lexicon's orally-delivered small molecule drug candidate for managing gastrointestinal symptoms associated with carcinoid syndrome. The clinical studies, conducted to date in healthy volunteers, indicated that the drug candidate reduced serotonin levels in humans as predicted by Lexicon's mouse models and preclinical research. Lexicon is planning to initiate a Phase 2 clinical trial of LX1032 in patients with carcinoid syndrome in the first quarter of 2009.
A copy of the presentation will be available on the company's corporate website at www.lexpharma.com.
The ENETS conference is a medical conference focused on diagnosis and treatment of neuroendocrine tumors including carcinoid. The meeting brings together leading neuroendocrine tumor experts from around the world in such fields as oncology, pathology, radiology, nuclear medicine, endocrinology, surgery and gastroenterology. The 2009 ENETS conference runs from March 5-7 in Granada, Spain.
Carcinoid syndrome is a chronic condition that is the result of metastatic neuroendocrine tumors that usually originate from the gastrointestinal tract. These tumors secrete large amounts of serotonin, which can cause a variety of symptoms including severe diarrhea and abdominal discomfort. LX1032 acts to reduce serotonin production by inhibiting tryptophan hydroxylase (TPH), a key enzyme in the synthesis of serotonin.
LX1032 is being developed in a product development collaboration with Symphony Capital Partners, L.P. and its co-investors.
Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by the company's research team. The company has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.
CONTACT: Jason Ray, Manager, Corporate Communications and InvestorRelations of Lexicon Pharmaceuticals, Inc., +1-281-863-3225, email@example.com
Web site: http://www.lexpharma.com/
Ticker Symbol: (NASDAQ-NMS:LXRX)
Terms and conditions of use apply
Copyright © 2009 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: March 2009